Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 19 for (lung OR pulmonary) AND surgery

Edit search filters
  1. Extension Trial on Efficacy /​ Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) (BOSTON-3)

    Jacksonville, FL

  2. Radiation Therapy in Treating Patients with Extensive Stage Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  3. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

    Jacksonville, FL

  4. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer

    Jacksonville, FL, Scottsdale/Phoenix, AZ

  5. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment

    Rochester, MN

  6. A Study of Whole-Brain Radiation Therapy with or without Avoiding the Hippocampus while Treating Patients with Limited or Extensive Stage Small Cell Lung Cancer

    La Crosse, WI, Albert Lea, MN, Eau Claire, WI, Mankato, MN, Rochester, MN

  7. Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)

  8. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  9. A Study of Afatinib Treatment for Patients with Epidermal Growth Factor Receptor Mutation Positive Non-Small Cell Lung Cancer, Who Are Age 70 or Older

    Scottsdale/Phoenix, AZ

  10. A Study of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment for Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer